April 2, 2019
Ocular Therapeutix™ Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
PDUFA Target Action Date Set for November 10, 2019 BEDFORD, Mass.–(BUSINESS WIRE)—-Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused…